TokenPost·
FDA Clears United Therapeutics for Phase 1 Trial of PAH Candidate
The open-label study will use a single ascending dose design in healthy participants and assess safety, tolerability and pharmacokinetics.
More news
- TokenPostYieldMax SPCX Option Income Strategy ETF Sets $0.472 Weekly Dividend.
- TokenPostSei Drafts Autobahn Plan After Internal Test Shows Sub-250-Millisecond Ordering
- TokenPostUHS Sees $175 Million to $200 Million Medicaid Supplemental Payment Headwind in 2027
- Crypto BriefingLondon Metal Exchange explores tokenizing off-warrant metal to boost revenue
- UnchainedAlexander Zahnd Gives Up Zilliqa CEO Role With No Successor Named as X-Bridge Stays Suspended
- Crypto BriefingCFTC to host public roundtable on 24/7 derivatives trading on Dec. 15